Showing results (121-130 of 202) with videos related to

Sort By:
Pageof 21
Blood|May 3, 2002
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyMichael J Keating, Ian Flinn, Vinay Jain, et al.
Leukemia Research|May 15, 2002
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndromeChung Wu Lin, Taghi Manshouri, Iman Jilani, et al.
Blood|March 23, 2006
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemiaCharles Koller, B Nebiyou Bekele, Xian Zhou, et al.
Transfusion|June 28, 2017
Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemiaCelina Montemayor-Garcia, Rebecca Coward, Maher Albitar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignanciesDavid A Rizzieri, Eric Feldman, John F Dipersio, et al.
Cancers|February 26, 2025
Updates on the Biological Heterogeneity of Mantle Cell LymphomaAndrew Ip, Maciej Kabat, Lindsay Fogel, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
Cancer|March 17, 2004
Thalidomide for patients with recurrent lymphomaBarbara Pro, Anas Younes, Maher Albitar, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disordersApostolia M Tsimberidou, Dawn E Colburn, Mary Alma Welch, et al.
Pageof 21